Article Text

Download PDFPDF
Fertility-Preserving Treatment in Young Women With Endometrial Adenocarcinoma: A Long-Term Cohort Study
  1. Chin-Jung Wang, MD*,
  2. Angel Chao, MD, PhD,,
  3. Lan-Yan Yang, PhD,§,
  4. Swei Hsueh, MD,,
  5. Yu-Ting Huang, MD,
  6. Hung-Hsueh Chou, MD,,
  7. Ting-Chang Chang, MD, and
  8. Chyong-Huey Lai, MD,
  1. * Divisions of Gynecologic Endoscopy and
  2. Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University;
  3. Gynecologic Cancer Research Center and
  4. §Biostatistics and Informatics Unit, Clinical Trial Center, Chang Gung Memorial Hospital; and Departments of
  5. Pathology and
  6. Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
  1. Address correspondence and reprint requests to Chyong-Huey Lai, MD, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, 5 Fu-Shin St, Kueishan, Taoyuan 333, Taiwan. E-mail: sh46erry{at}


Objective Growing evidence suggests that fertility-preserving treatment is feasible for young women with early-stage, low-grade endometrial carcinoma. However, published data on their long-term outcomes and prognostic factors remain scanty. We aimed to investigate the outcomes of young women receiving fertility-preserving treatment.

Methods Between 1991 and 2010, the outcomes of young women with grade 1 endometrioid endometrial carcinoma at presumed stage IA (without myometrial invasion) who underwent fertility-preserving treatment of megestrol acetate 160 mg/d with or without other hormonal agents were retrospectively analyzed.

Results We identified 37 eligible patients (median age, 32 years; range, 18–40 years). The median follow-up time was 78.6 months (range, 19.1–252.8 months). Complete response (CR) lasting more than 6 months was achieved in 30 (81.1%) women. Responders were significantly younger than nonresponders (P = 0.032). Of the 30 women who had a CR, 15 (50.0%) had disease recurrence. The 5-, 10-, and 15-year cumulative recurrence-free survival rates were 51.0%, 51.0%, and 34.0%, respectively. Notably, those recurred were significantly older (P = 0.003), and the time to CR was significantly longer (P = 0.043) than those without recurrence. One patient developed late recurrences at 156 months, and 2 patients developed ovarian metastasis (6 and 137 months from diagnosis). All the patients are currently alive.

Conclusions This study demonstrates the feasibility of high-dose megestrol acetate–based therapy for fertility preservation. The substantial risk of late recurrences highlights the need for long-term follow-up studies of large sample sizes with in-depth tumor and host molecular signatures.

  • Endometrial carcinoma
  • Megestrol acetate
  • Young age
  • Fertility-preserving treatment
  • Hysteroscopy
  • Long-term follow-up

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supported by grants from the National Science Council–Taiwan (NSC101-2314-B-182-043 to C.-J.W.) and the Chang Gung Medical Foundation (CMRPG391442 and BMRPG3A0011 to C.-H.L.).

  • The authors declare no conflicts of interest.